20 patents
Utility
KDM1A inhibitors for the treatment of disease
3 Oct 23
Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases.
Hugh Y. Rienhoff, Jr., John M. McCall, Michael Clare, Cassandra Celatka, Amy E. Tapper
Filed: 22 Sep 21
Utility
Pharmaceutical Formulations for Treating Diseases Mediated by KDM1A
21 Sep 23
Provided is a pharmaceutical composition comprising: N—((S)-5-((1R,2S)-2-(4-fluorophenyl)cyclopropylamino)-1-(4-methylpiperazin-1-yl)-1-oxopentan-2-yl)-4-(1H-1,2,3-triazol-1-yl)benzamide (Compound A), or a pharmaceutically acceptable salt thereof, and at least one stabilizer, pharmaceutical preparations thereof, and methods for the treatment a disease or disorder associated with KDM1A activity.
Amy TAPPER, Cassandra CELATKA, Patricia SOULLIAC, Parag VED, Namrata VORA
Filed: 23 Mar 23
Utility
KDM1A Inhibitors for the Treatment of Disease
10 Aug 23
The present disclosure relates to compounds and methods which may be useful as inhibitors of KDM1A for the treatment or prevention of diseases.
Amy E. TAPPER, Cassandra CELATKA, Michael CLARE, Hugh Y. RIENHOFF, JR.
Filed: 15 Dec 22
Utility
KDM1A inhibitors for the treatment of disease
23 May 23
Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases.
John M. McCall, Hugh Y. Rienhoff, Jr., Michael Clare
Filed: 1 Dec 20
Utility
Methods and Processes for the Preparation of KDM1A Inhibitors
6 Apr 23
Provided in this disclosure are methods for the synthesis of substituted 2-arylcyclopropylamines and 2-heteroarylcyclopropylamines and related compounds.
Amy E. TAPPER, Cassandra CELATKA, Arthur Glenn ROMERO, John M. MCCALL, Toni CHANCELLOR, Jian-Xie CHEN, Xuemei CHEN, He ZHAO, Betina BIOLATTO, Elisabeth C.A. BROT, Zhihua LI, Xiaoming LIAO
Filed: 15 Jun 22
Utility
KDM1A inhibitors for the treatment of disease
14 Feb 23
The present disclosure relates to compounds and methods which may be useful as inhibitors of KDM1A for the treatment or prevention of diseases.
Amy E. Tapper, Cassandra Celatka, Michael Clare, Hugh Y. Rienhoff, Jr.
Filed: 13 May 19
Utility
Lysine-specific Histone Demethylase Inhibitors for the Treatment of Myeloproliferative Neoplasms
5 Jan 23
Disclosed herein are methods for treating or preventing myeloproliferative neoplasms in a subject in need thereof, and for effecting specific clinically relevant endpoints, comprising administering a therapeutically effective amount of an LSD1 inhibitor.
Hugh Y. RIENHOFF, JR.
Filed: 2 Jun 22
Utility
Methods and processes for the preparation of KDM1A inhibitors
19 Jul 22
Provided in this disclosure are methods for the synthesis of substituted 2-arylcyclopropylamines and 2-heteroarylcyclopropylamines and related compounds.
Amy E. Tapper, Cassandra Celatka, Arthur Glenn Romero, John M. McCall, Toni Chancellor, Jian-Xie Chen, Xuemei Chen, He Zhao, Betina Biolatto, Elisabeth C. A. Brot, Zhihua Li, Xiaoming Liao
Filed: 16 Aug 17
Utility
KDM1A Inhibitors for the Treatment of Disease
10 Mar 22
Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases.
Hugh Y. RIENHOFF, JR., John M. MCCALL, Michael CLARE, Cassandra CELATKA, Amy E. TAPPER
Filed: 22 Sep 21
Utility
Compositions and Methods for Producing Stereoisomerically Pure Aminocyclopropanes
27 Jan 22
The present disclosure relates to compositions and methods for producing stereoisomerically pure aminocyclopropanes.
Amy E. TAPPER, Cassandra CELATKA, Arthur Glenn ROMERO, John M. MCCALL, Toni CHANCELLOR, He ZHAO, Betina BIOLATTO, Jian-Xie CHEN, Elisabeth C.A. BROT, Peter C. MICHELS, Venkat K. CHARI, Ian C. COTTERILL
Filed: 16 Aug 17
Utility
KDM1A inhibitors for the treatment of disease
25 Jan 22
Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases.
Hugh Y. Rienhoff, Jr., John M. McCall, Michael Clare, Cassandra Celatka, Amy E. Tapper
Filed: 1 Nov 19
Utility
Lysine-specific Histone Demethylase Inhibitors for the Treatment of Myeloproliferative Neoplasms
16 Dec 21
Disclosed herein are methods for treating or preventing myeloproliferative neoplasms in a subject in need thereof, and for effecting specific clinically relevant endpoints, comprising administering a therapeutically effective amount of an LSD1 inhibitor.
Hugh Y. RIENHOFF, JR.
Filed: 17 Jun 21
Utility
Lysine-specific Histone Demethylase As a Novel Therapeutic Target In Myeloproliferative Neoplasms
1 Jul 21
Disclosed herein are methods for treating or preventing myeloproliferative neoplasms in a subject in need thereof, and for effecting specific clinically relevant endpoints, comprising administering a therapeutically effective amount of an LSD1 inhibitor.
Hugh Y. RIENHOFF, JR.
Filed: 8 Jan 21
Utility
KDM1A Inhibitors for the Treatment of Disease
20 May 21
Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases.
John M. MCCALL, Hugh Y. RIENHOFF, JR., Michael CLARE
Filed: 1 Dec 20
Utility
Methods and Processes for the Preparation of KDM1A Inhibitors
13 May 21
Provided in this disclosure are methods for the synthesis of substituted 2-arylcyclopropylamines and 2-heteroarylcyclopropylamines and related compounds.
Amy E. TAPPER, Cassandra CELATKA, Arthur Glenn ROMERO, John M. MCCALL, Toni CHANCELLOR, Jian-Xie CHEN, Xuemei CHEN, He ZHAO, Betina BIOLATTO, Elisabeth C.A. BROT, Zhihua LI, Xiaoming LIAO
Filed: 16 Aug 17
Utility
KDM1A Inhibitors for the Treatment of Disease
22 Apr 21
The present disclosure relates to compounds and methods which may be useful as inhibitors of KDM1 A for the treatment or prevention of diseases.
Amy E. TAPPER, Cassandra CELATKA, Michael CLARE, Hugh Y. RIENHOFF, Jr.
Filed: 13 May 19
Utility
KDM1A inhibitors for the treatment of disease
4 Jan 21
Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases.
John M. McCall, Hugh Y. Rienhoff, Jr., Michael Clare
Filed: 18 Jun 19
Utility
KDM1A Inhibitors for the Treatment of Disease
9 Sep 20
Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases.
Hugh Y. RIENHOFF, JR., John M. MCCALL, Michael CLARE, Cassandra CELATKA, Amy E. TAPPER
Filed: 31 Oct 19
Utility
KDM1A Inhibitors for the Treatment of Disease
25 Mar 20
Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases.
John M. MCCALL, Hugh Y. RIENHOFF, Jr., Michael CLARE
Filed: 18 Jun 19
Utility
KDM1A inhibitors for the treatment of disease
30 Dec 19
Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases.
Hugh Y. Rienhoff, Jr., John M. McCall, Michael Clare, Cassandra Celatka, Amy E. Tapper
Filed: 11 Apr 18
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first